3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Gastrointestinal
2
Endocrine
2
Conditions
Breast Neoplasms
103
Carcinoma, Renal Cell
70
Neoplasm Metastasis
48
Neoplasms
37
Neuroendocrine Tumors
33
Kidney Neoplasms
27
Recurrence
19
Tuberous Sclerosis
18
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
16
Triple Negative Breast Neoplasms
15
Lymphoma
15
Lymphoma, Mantle-Cell
14
Lymphoma, Large B-Cell, Diffuse
14
Head and Neck Neoplasms
14
Glioblastoma
14
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
13
Stomach Neoplasms
12
Lung Neoplasms
12
Leukemia, Lymphocytic, Chronic, B-Cell
12
Hodgkin Disease
12
Brain Neoplasms
12
Sarcoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Glioma
11
Waldenstrom Macroglobulinemia
10
Lymphoma, Follicular
10
Carcinoma, Neuroendocrine
10
Interventions
lutetium Lu 177 dotatate
6
lanreotide
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
copper dotatate CU-64
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Gastro-enteropancreatic neuroendocrine tumor
×
Everolimus
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled